events Archives - Page 7 of 10 - Sanford Burnham Prebys
Institute News

An evening with autoimmune disorder experts

AuthorMonica May
Date

June 26, 2019

On June 20, 2019, nearly 100 community members, including many people living with autoimmune disorders and their loved ones, joined us at our latest SBP Insights event. The discussion featured unique perspective from three experts—a scientist, a doctor and a patient—on a single topic: autoimmune disorders. 

More than 50 million Americans have an autoimmune disorder, such as Crohn’s disease, psoriasis or rheumatoid arthritis. These conditions are often painful, chronic and debilitating. For unknown reasons, more than 80 percent of these patients are women. 

Scientists know these disorders occur when the immune system mistakenly attacks healthy tissue. But researchers still don’t understand why immunosuppressive treatments don’t work for everyone or know the initial trigger that causes the immune system to misfire. Answers to these fundamental questions could unlock insights that lead to new, effective medicines. 

“Before I was diagnosed, I thought doctors had it all sorted out. Now I know there is so much they don’t know,” says 17-year-old Madison Koslowski, who was diagnosed last year with juvenile idiopathic arthritis. She uses a wheelchair and cane for mobility while she works with her doctor to find a treatment that relieves her intense joint pain. “Right now, my friends are planning their future and figuring out where they will go to college. But for me, there are so many unknowns. I don’t know if I’m going to respond to the next medicine we try or if I will be really sick. I feel like my life is on pause. I have no idea when it will start again.”

Madison traveled from Los Angeles with her mother and a friend to hear race-car driver Angela Durazo speak about her journey with rheumatoid arthritis and learn what’s on the horizon for autoimmune treatments (read Angela’s story).

Following Angela’s presentation, Carl Ware, PhD, professor and director of the Infectious and Inflammatory Diseases Center at Sanford Burnham Prebys, took the stage and provided an overview of the science behind autoimmune disease. Ware also described his ongoing research collaboration with Eli Lilly, which recently led to a new Phase 1 clinical trial for autoimmune disorders. 

Hal Hoffman, MD, chief, division of allergy, immunology and rheumatology at UCSD and Rady Children’s Hospital, wrapped up the discussion with an overview of how he and his team are turning to rare immune disorders to understand the conditions as a whole. A Q&A followed the brief presentations. 

17-year-old Madison Koslowski (right), who was diagnosed last year with juvenile idiopathic arthritis, poses with race-car driver Angela.

17-year-old Madison Koslowski (right), who was diagnosed last year with juvenile idiopathic arthritis, poses with race-car driver Angela.

The discussion was moderated by Zaher Nahle, PhD, CEO of the Arthritis National Research Foundation.

Join us at our next SBP Insights discussion, which focuses on pancreatic cancer and takes place on November 21, 2019. Event details.

Institute News

Stepping into a scientist’s shoes at the Cancer Center Open House

AuthorMonica May
Date

June 20, 2019

Cancer research has led to new insights and novel medicines that have transformed the lives of parents, grandparents and children around the world. Yet cancer remains the number-one cause of death in San Diego (nationally, it is the second-leading cause of death). The quest for new and better treatments—and a world free of the disease—remains urgent. 

On June 13, 2019, the San Diego community—including many cancer survivors and their loved ones—had a unique opportunity to step into the shoes of a cancer researcher and see how cancer drugs are discovered at the open house of our NCI-designated Cancer Center. The facility is one of only seven National Cancer Institute (NCI)–designated basic research cancer centers in the nation. 

Following an introduction by Garth Powis, D. Phil., professor and director of the NCI-designated Cancer Center, guests embarked on guided lab tours. Attendees discovered how we’re working to find better ways to combat cancer, viewed highly specialized equipment—such as machines that model the low-oxygen environment surrounding a tumor—and donned lab coats to catch a glimpse of our ultra-high-throughput drug screening robot in action at our Prebys Center for Drug Discovery. The state-of-the-art technology at the Prebys Center can screen hundreds of thousands of potential drug candidates in one run, accelerating the time it takes to find new, promising compounds that may become tomorrow’s cancer treatments.

Guests also learned how San Diego, with a multitude of world-class research institutes, universities and biotech companies, is shaping the future of cancer diagnosis and treatment. And our Community Advisory Board, comprised of cancer research advocates and cancer survivors, were on hand to share the importance of factoring in patients’ perspectives as breakthrough science moves from “bed to bedside.”

See the science in action in these event photos.

Missed the event? We hope you can join us at our next open house in November. The event is free and open to the public. Check for more details at sbpdiscovery.org/calendar.

Many thanks to our Community Advisory Board (CAB), the host of the open house. Comprised of nine cancer research advocates, including many cancer survivors, this committee strives to create a dialogue between our scientists and the community. We are grateful for CAB’s efforts surrounding the event, which included helping our scientists prepare lay-friendly presentations and posters that were critical to the event’s success.

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

Getting groovy for a good cause at Bring It!

AuthorMonica May
Date

May 9, 2019

From the moment guests stepped into the disco-lit room, it was clear Bring It! was not your typical fundraiser. 

Donned in bell bottoms, sequined bodysuits and platformed heels, this year’s guests sampled hors d’oeuvre’s supplied by roller-blading servers and grooved to classics such as “Stayin’ Alive” and “Dancing Queen.” 

The 70’s-themed event, held on May 2, 2019, at the Del Mar Fairgrounds, drew a crowd of more than 400 attendees—the largest yet—a testament to the hard work and dedication of co-chairs Juli Oh and Matt Browne, and Sarah and David Szekeres. John Weisbarth, host of Tiny House Nation and San Diego native, emceed the event for the third year in a row.

While fun was had by all, the night’s mission was never far from anyone’s mind: fundraising for our Institute’s work to find cures for diseases such as Alzheimer’s, cancer, heart disease, diabetes and more. 

Co-chair Sarah Szekeres shared her personal story about why research is important to her: “Learning I have the BRCA2 gene mutation, which puts me at a greater risk of breast and ovarian cancer, has been an overwhelming and frightening experience for me and my family. It’s through basic research that we will develop effective medicines or tests that prevent, diagnose or treat disease—and create a future where my daughter, and her children and grandchildren, aren’t afraid of cancer or Alzheimer’s or the many serious diseases our society faces today.”

Guests vied for an opportunity to participate in onstage competitions—a spot so coveted it was raffled to the highest bidder. Top-scoring teams partook in absurdly hilarious games, such as “Hungry Hungry Human,” where guests attempted to collect plastic balls from an inflated pool while wheeled on a dolly; and “Rocky,” where participants furiously boxed and ran in place to reach the most steps on a pedometer. Despite wearing wigs and hats, contestants even braved a bobbing-for-apples style competition involving candy encased in a Jello Mold.

Altogether, Bring It! certainly puts the “fun” in “fundraising needs.” We hope to see you next year—stay tuned for more details about the date and theme of the event.  

We are extremely grateful to the event’s generous sponsors, including Alexandria Realty, Heron Therapeutics, Marleigh and Alan Gleicher, Cooley, Marilena and Greg Lucier, Retrophin, Domain Associates, Robin and Hank Nordhoff, Jeanne Herberger, PhD, Moon Valley Nurseries, Bank of America Merrill Lynch, Luke and Elizabeth Bonacci, Sarah and David Szekeres, Jonell and Gregory Tibbitts, Court and Julie Turner, Dulcy and Mason Matthies, Josie and Jim Myers, Marie Simmons, Arena Pharmaceuticals, BDO, CBRE, Creative Fusion, Cushman & Wakefield, IDT, Deloittte & Touche, Farrell Family Foundation, iProtean, KPMG, Johnson & Johnson, Marsh & McLennan Agency, Neurocrine Biosciences, Oxford Finance, Pegasus Building Services, UnionBank, Cabrillo Advisors, Square1bank and USI Insurance Services. 

Watch a fun-filled KUSI segment about the event. 

Head to our Facebook page to view event photos; search #BringIt19 to find more content. 

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

Sanford Burnham Prebys and Salk co-organize third annual La Jolla Aging Meeting

AuthorMonica May
Date

April 11, 2019

“Excellent presentation!”
“We should connect—we have more samples coming soon.” 
“Feel free to reach out, we’re looking to partner so I’d love to hear more about your research.”

These exchanges, overheard at the 3rd annual La Jolla Aging Meeting held on March 29, 2019, at the Salk Institute, illustrate the importance of uniting scientists focused on a common goal: In this case, uncovering the root causes of aging. 

As in previous years, the 2019 meeting was co-organized by Sanford Burnham Prebys’ Malene Hansen, PhD, and Peter Adams, PhD; and Salk’s Jan Karlseder, PhD A key goal of the event is to feature research by local scientists studying the molecular mechanisms of aging, while fostering connections and building relationships that advance new discoveries. More than 200 researchers, primarily from the San Diego area, attended the meeting. 

Aging is the main risk factor for many of the serious diseases our society faces today, including cancer, heart disease and Alzheimer’s. As the U.S. population grows older due to the natural aging of the Baby-Boomer generation, the need to understand the underlying causes of aging becomes more urgent. The number of Americans who are age 65 or older is projected to double from nearly 48 million in 2015 to more than 90 million in 2060, according to the United States Census Bureau. 

The diversity of presentations given—from the role of supportive brain cells called astrocytes and cellular recycling (autophagy) to long-lived proteins in mitochondria (the cell’s power generator)—reflects the complexity of the field. A poster session was also held during the symposium, providing an opportunity for up-and-coming scientists to share their recent data. 

La Jolla Aging Meeting tweet

For scientists new to the area, the meeting provided a key opportunity to build relationships.

“It’s unlikely there will be any single factor responsible for aging,” says Matt Kaeberlein, PhD, professor at the University of Washington and the symposium’s keynote speaker. “I am encouraged to see so many people interested in diverse aspects of aging biology at this symposium. By advancing each of these distinct research areas, and working together, we will make progress in understanding the underlying aging process.”

The full list of speakers follows. Make sure to save the date for next year’s meeting, which will be held on March 27, 2020. 

  • Matt Kaeberlein, PhD, University of Washington (keynote) – New insights into mechanisms by which mTOR modulates metabolism, mitochondrial disease and aging
  • Isabel Salas, PhD, Allen lab, Salk – Astrocytes in aging and Alzheimer’s disease
  • David Sala Cano, PhD, Sacco lab, Sanford Burnham Prebys – The Stat3-Fam3a axis regulates skeletal muscle regenerative potential
  • Tina Wang, Ideker lab, University of California, San Diego – A conserved epigenetic progression aligns dog and human age
  • Rigo Cintron-Colon, Conti lab, Scripps Research – Identifying the molecules that regulate temperature during calorie restriction
  • Nan Hao, PhD, University of California, San Diego – Programmed fate bifurcation during cellular aging
  • Shefali Krishna, PhD, Hetzer lab, Salk – Long-lived proteins in the mitochondria and their role in aging
  • Sal Loguercio, PhD, Balch lab, Scripps Research – Tracking aging with spatial profiling
  • Alva Sainz, Shadel lab, Salk – Cytoplasmic mtDNA-mediated inflammatory signaling in cellular aging
  • Anthony Molina, PhD, University of California, San Diego – Mitochondrial bioenergetics and healthy aging: Advancing precision healthcare for older adults
  • Alice Chen, Cravatt lab, Scripps Research – Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan
  • Robert Radford, PhD, Karlseder lab, Salk – TIN2: Communicating telomere status to mitochondria in aging
  • Jose Nieto-Torres, PhD, Hansen lab, Sanford Burnham Prebys – Regulating cellular recycling: role of LC3B phosphorylation in vesicle transport

Prizes for the best poster presentations were awarded to the following scientists: 

  • Hsin-Kai Liao, PhD, Juan Carlos Izpisua Belmonte’s lab, Salk  
  • Yongzhi Yang, PhD, Malene Hansen’s lab, Sanford Burnham Prebys
  • Tai Chalamarit, Sandra Encalada’s lab, Scripps Research 

Thank you to our generous sponsor, the Glenn Foundation for Medical Research, and to NanoString for donating the prizes received by the poster presenters.  

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.
 

Institute News

Inspiring future scientists at the STEM EXPO

AuthorMonica May
Date

March 25, 2019

Armed with wiggly worms and striped zebrafish, on Saturday, March 2, more than 20 volunteers from Sanford Burnham Prebys helped kids and their families learn about the power of DNA at the San Diego Festival of Science & Engineering’s EXPO Day. 

One of the largest STEM (Science, Technology, Engineering and Math) festivals in the U.S., this year’s event featured more than 130 interactive exhibits designed to ignite a passion for science in K–12 students. Despite an uncharacteristically rainy morning, an estimated 17,000 people attended. 

For Joseph Lancman, PhD, a postdoctoral researcher at our Institute who was the first in his family to graduate from college, the festival was an opportunity to provide children with the experience he wishes he’d had as a kid.

“Growing up, I knew I was interested in human health, but I had no idea that research was an option,” Lancman says. “Like many kids, I thought I wanted to be a doctor. But in college, I quickly learned that I wanted to know more. I wanted to know what causes disease and how scientists go about finding cures.” 

STEM EXPO 2019 Joseph Lancman and son

Dr. Lancman and his son

At our booth, postdoctoral researchers, graduate students and staff helped children don paper lab coats and explore DNA-themed activities. 

Children were able to see live worms with DNA mutations that affect their movement, courtesy of the lab of Malene Hansen, PhD, professor in the Development, Aging and Regeneration Program. Compared to normal worms, some mutant worms moved mindlessly in circles, and others remained relatively immobile—illustrating how changes in a DNA sequence can dramatically affect life.

At the adjacent station, provided by the lab of Duc Dong, PhD, assistant professor in the Human Genetics Program, children squinted through microscopes and peered into fish tanks to observe how DNA changes can dramatically affect the heartbeat of zebra fish—one of the most powerful model organisms used to study vertebrate biology. 

Lancman, who works in Dong’s lab, took care to explain the exhibit in child-friendly language (he credits his four-year-old son for helping him develop this skill). 

“I want kids to know that science is like a puzzle,” he explains. “It takes time to put all the pieces together, but when you’re done, you can see the big picture—and that big picture can lead to improving human health.”

Institute News

Families find hope at our 10th Annual Rare Disease Day Symposium

AuthorMonica May
Date

March 25, 2019

The unofficial theme of Sanford Burnham Prebys’ 10th annual Rare Disease Day symposium can be summarized in one word: hope. 

This year’s event focused on rare bone disorders and bone cancers, with a special emphasis on a condition called multiple hereditary exostoses (MHE) that causes numerous bone tumors in children. Until now, children with MHE had only one treatment option: repeated surgeries to remove these tumors. 

Now, the first medicine, called palovarotene, that may be able to slow or halt this bone growth is being tested in a clinical trial—potentially saving these children from a lifetime of painful surgeries. Yu Yamaguchi, MD, PhD, symposium chair and professor in Sanford Burnham Prebys’ Human Genetics program, participated in the key research needed in order for the clinical trial to begin.

“For the first time, a diagnosis doesn’t feel like a life sentence,” says Greta Falkner, who attended the symposium with her 8-year-old son, Jackson Falkner. Jackson has MHE and has undergone 13 surgeries to date. “Today we have hope for a cure.”

The launch of a study evaluating palovarotene as an MHE treatment is the result of decades of hard work and collaboration between scientists, clinicians, Clementia Pharmaceuticals (now Ipsen) and the MHE Research Foundation—a patient advocacy and support group. 

The symposium featured an all-star lineup of distinguished speakers in the field of skeletal biology and MHE research, including keynote speaker Henry Kronenberg, MD, of Massachusetts General Hospital and Maurizio Pacifici, PhD, of Children’s Hospital of Philadelphia, whose research formed the scientific rationale for the use of the drug in MHE. The event was sponsored by the MHE Research Foundation and Clementia Pharmaceuticals. 

“We are so grateful that Sanford Burnham Prebys holds this Rare Disease Day symposium to bring together all the important players in rare disease drug discovery: scientists, doctors, families and drug companies. It is literally ‘bench to bedside’ at one event,” says Sarah Ziegler, who co-founded the MHE Research Foundation with Craig and Susan Eaton after Sarah’s son was diagnosed with MHE in 1993 (when little to no information was available on the disease). “Foundations like ours rely on the research of scientists like Drs. Yamaguchi and Pacifici to find new medicines for patients—and the arrival of the first potential treatment for MHE is the perfect example of the power of this research.” 

Multiple parents and children with MHE, some of whom are enrolled in the clinical trial, attended the event. For most of these children, this was the first time they’d met another person with their condition. 
 

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

5 takeaways from Insights: Heart Disease

AuthorMonica May
Date

February 15, 2019

It’s easy to forget about the fist-sized organ in our chest. But the heart is arguably the most important muscle in the body. We can’t live without it, after all. 

To help educate the public about heart health and share the latest scientific advances, this month Sanford Burnham Prebys Medical Discovery Institute (SBP) invited the San Diego community to a free panel discussion focused on the heart. 

More than 70 community members attended the event, whose speakers included cardiologist Anthony N. DeMaria, MD; Jack White, chair in Cardiology, professor of Medicine, founding director, Sulpizio Cardiovascular Center at UC San Diego Health; Donna Marie Robinson, an individual living with heart failure; and heart researcher Karen Ocorr, PhD, assistant professor, Development, Aging and Regeneration Program at SBP. Jennifer Sobotka, executive director at the American Heart Association San Diego, moderated the discussion.

In a special introduction provided by Rolf Bodmer, PhD, director and professor in the Development, Aging and Regeneration Program at SBP, he explained that his heart research uses model organisms such as the fruit fly. He quipped, “Which some of you didn’t even know had a heart.” 

The ensuing discussion was robust and insightful. Below are five important takeaways: 

  1. Heart disease is the number-one killer of Americans. Nearly half of American adults have some form of heart or blood vessel disease.
  2. Obesity is an epidemic in America. In the 1960s, approximately 13 percent of American adults were obese, according to the Centers for Disease Control (CDC). Today, that number has tripled to nearly 40 percent. DeMaria illustrated this point with a colored map showing obesity’s prevalence during each decade, which drew gasps from the crowd. 
  3. Know your numbers. Donna Marie was healthy and fit, so she didn’t think that a fainting episode could have been heart disease. “My cardiologist saved my life,” she said. Now, she encourages everyone to “know your numbers, including your cholesterol level and your blood pressure.” 
  4. Rethink swatting that pesky fruit fly. We share 80 percent of disease-causing genes with the tiny insect, including ion channels that keep the heart pumping. For this reason scientists are studying fruit-fly hearts in an effort to learn about the many mysteries of the heart, such as how the rhythm disorder atrial fibrillation (AFib) arises. 
  5. Consider moving to Italy. Just about everyone wants to know which science-backed diet to follow for optimal health. DeMaria explained that the most robust data supports eating a Mediterranean diet rich in fruits, vegetables and olive oil.

Read the La Jolla Light’s coverage of the event. 

Institute News

Nobel laureate Michael Rosbash presents his latest fruit-fly research at Sanford Burnham Prebys

AuthorMonica May
Date

February 8, 2019

You may want to reconsider swatting that pesky fruit fly: Despite appearances, we share more than half of our genes with the tiny insect. For this reason—and their shorter life span and simpler genome—researchers often use the flies as models for human health and disease. 

Nobel laureate Michael Rosbash, PhD, is one such scientist. A self-described “fly chauvinist,” this month he visited SBP to present his latest research on the circadian rhythm of fruit flies. The event quickly became standing room only. 

Rosbash received the 2017 Nobel Prize in Physiology or Medicine, along with Jeffrey Hall and Michael Young, for their work uncovering the molecular timekeepers behind circadian rhythm. Their work was conducted in fruit flies, but has since unlocked new discoveries in animals and plants. 

Rolf Bodmer, PhD (pictured left), who introduced Rosbash (pictured right), is using fruit flies to uncover how our heart develops and ages, with a particular focus on a heart rhythm disorder called AFib. Nearly 10 percent of people over the age of 65 develop the condition, a leading cause of stroke, but we don’t know its cause, and there is no cure. By studying AFib in fruit flies, Bodmer and his team, which includes a cardiologist at Scripps Clinic, are hoping to learn the cause of the disorder and find effective treatment(s). 

While he has all the reason in the world to have an ego, Rosbash remains humble and down-to-earth. He ended his presentation by thanking his lab, without whom he would “not have a job and such prizes.” 

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

SBP scientist presents at Fleet Science Center to help the public better understand precision medicine

AuthorMonica May
Date

January 29, 2019

From how much coffee we can tolerate to the amount of weight we can lift, our bodies differ from one another in myriad ways. But when it comes to medicine, historically every patient with the same disease or condition has received the same treatment—even though individual responses vary wildly. 

Now, technological advances are enabling medicine to move from “one size fits all” to tailored treatments based upon one’s specific genes. This approach is called precision medicine. 

This December, under the dome of the Fleet Science Center’s IMAX theater, Jessica Rusert, PhD, a postdoctoral researcher in the lab of Robert Wechsler-Reya, PhD, explained the promise and potential of precision medicine to a crowd of nearly 100 people as part of the museum’s Senior Monday presentation series (if interested, check out the 2019 schedule). 

We caught up with Rusert to learn more about the goals of precision medicine and her work in the Wechsler-Reya lab. 

Before the advent of precision medicine, how did doctors typically treat patients? 
In the past, all patients who had the same disease—say, breast cancer—received the same treatment, which was most likely surgery followed by chemotherapy and radiation. Your treatment might change if you have more advanced disease—in which case the approach would be more aggressive. But typically treatment was based upon physical criteria: the location of the tumor, your symptoms or how the tumor looks under a microscope. That’s not to say this is a bad approach; it was simply the only information doctors and scientists had to work from. 

What catalyzed the movement from one size fits all to personalized treatment?
The invention of DNA sequencing has revolutionized personalized medicine. As the cost of sequencing decreases and the use of the technology swells, we will glean even more information from the genome, and personalized medicine will expand further to new areas. 

What is the ultimate goal of precision medicine? 
Precision medicine aims to treat the right patient, with the right drug, at the right time.

How far away is precision medicine from this goal? 
We are making inroads, but it is still early days for precision medicine. Currently, we are making the most progress in cancer. But despite these advances, the vast majority of cancers—including the pediatric brain cancer our lab studies—are treated with surgery, chemotherapy and radiation. 

As scientists learn more about the underlying cause of disease(s), precision medicine will expand to new cancers and new disease areas. These advances are happening now, and for some cancers, the outlook is already much better than it used to be. Perhaps one day we will have personalized treatments for schizophrenia and autism. The approach is mostly limited by how much we know about a disease. 

What is an example of a precision medicine? 
The breast cancer treatment Herceptin® is a great example of a precision medicine. 

Cells in our body use molecular antennae called receptors to sense and respond to their environment. One receptor, called HER2, controls cellular growth, and is involved in the development of breast cancer. 

Herceptin works by blocking the HER2 receptor. Then, the receptor can’t tell cells to grow, and tumor growth stops. 

However, this medicine only works if your tumor cells have this receptor. HER2-positive breast cancer means your cells have this receptor. HER2-negative breast cancer means you do not have the receptor, and thus Herceptin wouldn’t work for you. So people with breast cancer are tested to ensure they have the HER2 receptor before receiving Herceptin. 

Herceptin has saved thousands of lives. It is a true testament to the power of precision medicine. 

What was a popular question from the audience?
A lot of people wondered if there’s a way to prevent cancer. This is understandable—cancer is scary, and we want to do all we can to stop it. But it’s a difficult question to answer. The science isn’t there yet. We are only just now starting to understand how to help people who have acute disease. We may understand how to prevent cancer one day—but that will take decades, not years. 

How do you use precision medicine in your work?
In the Wechsler-Reya lab, we are working to find personalized treatments for children with brain cancer. We are studying the most common malignant pediatric brain cancer, called medulloblastoma. 

Children with medulloblastoma undergo surgery to remove the tumor and then undergo chemotherapy and radiation treatment. This treatment is hard for adults to go through—and even more devastating for a developing child. The treatment leaves long-term effects, including cognitive impairment and increased risk of other cancers due to the DNA damage caused. A treatment that reduces or eliminates these side effects is urgently needed. 

Scientists are learning that medulloblastoma is not one cancer, but actually four clearly defined subgroups. We are working to better understand these subgroups so we can develop targeted treatments that are customized to each cancer type (read the lab’s recent discovery). 

Where is precision medicine heading in the future? 
Right now, most precision medicine focuses on our DNA, but there are many other ways we differ from one another. But increasingly, scientists are working toward precision medicine that also takes into account RNA, proteins, our metabolism, the epigenome (molecular tags on DNA) and more.

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

World-renowned scientists speak at SBP’s symposium on a booming research area: epigenetics

AuthorMonica May
Date

November 28, 2018

DNA contains more information than scientists previously thought. A booming field of research called epigenetics is uncovering DNA alterations that affect whether genes are turned on or off—without changing a single base pair. 

These epigenetic changes may be physical, such as winding or unwinding DNA to change its accessibility—akin to opening or closing a door. Other changes can be chemical, such as adding molecular tags that turn genes on or off—like a highlighter calling out special text to a reader. 

On October 29, 2018, more than 300 scientists gathered at SBP’s 39th Annual Symposium to hear the latest connections between epigenetics and development, aging, and diseases such as cancer. Researchers are particularly interested in this field because modifying epigenetic changes could be easier than editing the body’s underlying genetic code—and advances are leading to new medicines. 

Organized by SBP professors Peter Adams, PhD; Ani Deshpande, PhD; and Lorenzo Puri, MD, PhD, the event’s speakers hailed from Harvard Medical School, Massachusetts Institute of Technology, Stanford University and other world-renowned institutions. 

Tweet by scientists praising the symposium
  USC assistant professor Bérénice A. Benayoun, PhD,
  praised the symposium on Twitter

After a welcome by SBP’s President Kristiina Vuori, MD, PhD, talks commenced on topics ranging from the role of epigenetics in prostate cancer, development of the heart and aging. Unpublished work was frequently presented, meaning that attendees received the most up-to-date results available. 

A full list of speakers is listed below. To read more insights, follow #SBPsymposium on Twitter. And be sure to look out for next year’s symposium, which will focus on neurodegenerative diseases.

  • Anne Brunet, Stanford University – Epigenetic and metabolic regulation of aging 
  • Chris Glass, University of California, San Diego – Nature and nurture of tissue resident macrophages 
  • Cigall Kadoch, Dana-Farber Cancer Institute and Harvard Medical School – Structure and function of mammalian SWI/SNF complexes in human cancer 
  • Manolis Kellis, Massachusetts Institute of Technology – From genomics to therapeutics: dissection and manipulation of human disease circuitry at single-cell resolution 
  • Peter Lewis, Wisconsin Institute for Discovery – Mechanistic dissection of oncogenic histone mutations 
  • Barbara Meyer, University of California, Berkeley – Dynamic control of X-chromosome topology and gene expression during development via chromatin modification and condensing 
  • Raul Mostoslavsky, Harvard Medical School – Linking epigenetics, metabolism and cancer: new clues from SIRT6
  • Bing Ren, University of California, San Diego – Remodeling of chromatin organization during human cardiomyocyte differentiation 
  • Peggy Farnham, University of Southern California – CRISPR-mediated deletion of prostate cancer risk elements identifies repressive chromatin loops